Talphera, INC 10-Q quarterly reports

Talphera, Inc. reported a net loss of $4.3 million for Q2 2026, with cash reserves dwindling, raising concerns about its ability to fund operations beyond the next twelve months.

Talphera, Inc. filed its Q1 2026 Form 10-Q, detailing ongoing development efforts for Niyad, continued net losses, and a need for additional capital, while also addressing a Nasdaq minimum bid price deficiency.

Talphera, Inc. reported a reduced net loss for the nine months ended September 30, 2025, bolstered by recent capital raises totaling $21.3 million, but continues to face substantial doubt about its ability to continue as a going concern.

Talphera, Inc. reported continued net losses and negative cash flows for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite efforts to reduce operating expenses and secure new financing.

Talphera Inc. announces its Q1 2025 financial results, highlighting a net loss of $2.6 million and ongoing efforts to advance its Niyad program while addressing concerns about its ability to continue as a going concern.

Talphera Inc. reported its Q3 2024 results, highlighting a net loss of $3.4 million and a strategic focus on the development of its Niyad product candidate, while navigating ongoing financial constraints.

Talphera Inc. reported its second quarter 2024 financial results, highlighting progress in the development of its lead product candidate, Niyad, and a strategic sale of future payments related to DSUVIA.

Talphera Inc. announced its first quarter 2024 results, highlighting a strategic shift towards its nafamostat product candidates and securing additional funding through a sale of future payments and a private placement.